Lack of effect of captopril on the metabolism of an artificial lipid emulsion similar to chylomicrons in hypertensive hypercholesterolemic patients;Ausência de efeito do captopril no metabolismo de uma emulsão lipídica artificial semelhante aos quilomícrons em pacientes hipertensos e hipercolesterolêmicos

Arquivos Brasileiros de Cardiologia

Volumn 83, Issue 6, 2004, Pages 508-515

  Alves, Renato J ^b   Diament, Jayme ^b   Amâncio, Rosângela F ^b   Forti, Neusa ^b   Maranhão, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

Captopril; Chylomicrons; Lipoproteins; Metabolism

Indexed keywords

APOLIPOPROTEIN; CAPTOPRIL; CHOLESTEROL; CHOLESTEROL OLEATE; CHYLOMICRON; LIPID; LIPID EMULSION; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; CHOLESTEROL ESTER;

ADULT; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PROTEIN METABOLISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; EMULSION; METABOLISM; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CHOLESTEROL; CHOLESTEROL ESTERS; CHYLOMICRONS; EMULSIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED;

EID: 11944274807     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988;116:1729-1734.
2. Lithell H. Effect of anti-hypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14:203-209.
3. Ferrara LA, Marino LD, Russo O, et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensive Study. Hypertension 1993;21:97-104.
4. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-2192.
5. Mahley RW, Ji ZS. Remnant lipoprotein: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1-16.
6. Maranhão RC, Feres MC, Martins MT, et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 1996;126:15-25.
7. Bernardes-Silva H, Toffoletto O, Bortolotto LA, et al. Malignant hypertension is accompanied by marked alterations in chylomicron metabolism. Hypertension 1995: 26:1207-1210.
8. Borba EF, Bonfa E, Vinagre CG, et al. Chylomicrons metabolism is markedly altered in systemic lupus erythematous. Arthritis Rheum 2000;43:1033-1040.
9. Vinagre CG, Stolf NA, Bocchi E, et al. Chylomicron metabolism in patients submitted to cardiac transplantation. Transplantation 2000;69(4):532-537.
10. Santos RD, Ventura LI, Sposito AC, et al.The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc Res 2001;49:456-465.
11. Sposito AC, Maranhão RC, Vinagre CG, et al. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis 2001;154:455-461.
12. Joint National Committee. VI report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. 1997; NIH, no 98: 4080.
13. Oliveira HCT, Hirata MH, Redgrave TG, et al. Competition between chylomicrons and their remnants for plasma removal: a study with artificial emulsion models of chylomicrons: Bichem Biophys Acta 1988; 958: 211-217.
14. Mesquita CH. Análise compartimental auxiliar. São Paulo: Instituto de Pesquisas Energéticas e Nucleares(IPEN). Publicações IPEN 1994.
15. Redgrave TG, Maranhão RC. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985;835:104-112.
16. Redgrave TG, Ly HL, Quintão ECR, et al. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like emulsions in rats and man. Biochem J 1992;293:843-847.
17. Groot PHE, van Stiphout WAHJ, Krauss XH, et al. Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arteriosclerosis Thromb 1991;11:653-662.
18. Simons LA, Dwyer T, Simons J, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-189.
19. Zilversmit DB. Atherosclerosis: A post-prandial phenomenon. Circulation 1979; 60:473-485.
20. Simpson HS, Williamson CM, Olivecrona T, et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atheroclerosis 1990;85:193-202.
21. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the pos-prandial state. Arteriosclerosis Thromb 1992;12:1336-1345.
22. Iaina A, Silverberg DS, Wollman Y, et al. Post-prandial intestinal-derived chylomicron and chylomicron remnants in essential hypertensive patients before and after prolonged captopril therapy. Am J Hypertens 1995;8:34-39.
23. Deshaies I, Geloen A, Paulin A, et al. Restoration of lipoprotein lipase activity in insulin-dependent rats by insulin infusion is tissue especific. Can J Physiol Pharmacol 1991;69:746-751.
24. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991;11:1192-1203